Technical Data
P9053-26M7
PTGER3 (Prostaglandin E2 Receptor EP3 Subtype, PGE Receptor EP3 Subtype, PGE2 Receptor EP3 Subtype, PGE2-R, Prostanoid EP3 Receptor)
Description:
Receptor for prostaglandin E2 (PGE2); the EP3 receptor may be involved in inhibition of gastric acid secretion, modulation of neurotransmitter release in central and peripheral neurons, inhibition of sodium and water reabsorption in kidney tubulus and contraction in uterine smooth muscle. The activity of this receptor can couple to both the inhibition of adenylate cyclase mediated by G-I proteins, and to an elevation of intracellular calcium. The various isoforms have identical ligand binding properties but can interact with different second messenger systems.

Applications:
Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
ELISA: 1:2000
Western Blot: 1-3ug/ml, observed in human adipose, kidney, pancreas and placenta lysates on ~55kD bands
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabAffinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanGoat
Concentration:
~0.5mg/ml
Immunogen:
Synthetic peptide corresponding to KLLREPCSVQLS, from human PTGER3, at C-terminal of the protein (NP_000948.2, NP_942005.2, NP_942006.1).
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in Tris saline, 0.02% sodium azide, pH 7.3, 0.5% BSA.
Specificity:
Recognizes human PTGER3.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Sarrazin P, Hackett JA, Fortier I, Gallant MA, de Brum-Fernandes A. Role of EP3 and EP4 prostaglandin receptors in reorganization of the cytoskeleton in mature human osteoclasts. J Rheumatol. 2004 Aug;31(8):1598-606.